Inferred clonal hematopoiesis from tumor DNA sequencing among men with prostate cancer: correlation with somatic tumor alterations and outcomes
The Oncologist · 04.04.2025 · 30 (4)
DOI: 10.1093/oncolo/oyaf049 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 22.04.2025. Verfasst von Yasaman Iranmanesh und 14 weiteren Autor:innen. Beteiligte Einrichtung: Sidney Kimmel Comprehensive Cancer Center, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, United States. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Clonal Hematopoiesis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Winn Career Development, V Foundation.
Abstract (Originalsprache)
Background
Clonal hematopoiesis (CH) may be inferred from clinical next-generation sequencing (NGS) of tumor tissue. The clinical significance of inferred CH when detected as part of routine tumor sequencing is not well established and it is unknown whether or not CH is associated with other somatic mutations in tumors of men with prostate cancer.
Methods
We performed a retrospective review of clinical-grade NGS results from primary prostate tissue at a single institution. NGS reports were reviewed for the presence of pathogenic mutations in a panel of 27 genes commonly known to be mutated in CH. Overall survival from time of diagnosis and association with somatic alterations were interrogated.
Results
A total of 396 patients were included, with a median follow-up of 7.8 years (range 0.2-21.4 years). Approximately 12% of patients had inferred CH detected (n = 46) with ASXL1, TET2, and DNMT3A being the most commonly affected genes. In univariate analysis, those with inferred CH had an 81% increased risk of death compared to those without inferred CH (hazard ratio 1.8, 95% CI 1.1, 3.1, P = .03). This was attenuated after controlling for age at diagnosis and race (HR 1.1, 95% CI 0.6, 2.0, P = .77). Those with inferred CH were more likely to have pathogenic somatic mutations in PIK3CA (15% vs 4%), CTNNB1 (13% vs 2%) and BRCA1 (4% vs 0.3%).
Conclusion
Inferred CH is commonly detected on tumor-tissue NGS testing but does not clearly have a negative prognostic impact after adjusting for age. It may also be associated with the identification of other somatic driver mutations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sidney Kimmel Comprehensive Cancer Center, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, United States.
- UPMC Western Maryland, Department of Internal Medicine. Cumberland, MD 21502, United States.
- Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, United States.
- Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, United States.
ORCID-Profile: Catherine H Marshall
Förderung
- NCI NIH HHS
- Winn Career Development
- V Foundation
- Prostate Cancer Foundation
- Department Of Defense
- National Cancer Institute
Zitieren
APA
Iranmanesh, Y., Omar, N., Rasouli, A., Baras, A., Pasca, S., Gondek, L. P., Tsai, H. L., Denmeade, S. R., Carducci, M. A., Paller, C. J., Markowski, M. C., Luo, J., Eisenberger, M. A., Antonarakis, E. S., & Marshall, C. H. (2025). Inferred clonal hematopoiesis from tumor DNA sequencing among men with prostate cancer: correlation with somatic tumor alterations and outcomes. The Oncologist, 30(4). https://doi.org/10.1093/oncolo/oyaf049
Vancouver
Iranmanesh Y, Omar N, Rasouli A, Baras A, Pasca S, Gondek LP, et al. Inferred clonal hematopoiesis from tumor DNA sequencing among men with prostate cancer: correlation with somatic tumor alterations and outcomes. The Oncologist. 2025;30(4). doi:10.1093/oncolo/oyaf049
BibTeX
@article{Iranmanesh2025,
author = {Iranmanesh, Yasaman and Omar, Noha and Rasouli, Arya and Baras, Alex and Pasca, Sergiu and Gondek, Lukasz P and Tsai, Hua-Ling and Denmeade, Samuel R and Carducci, Michael A and Paller, Channing J and Markowski, Mark C and Luo, Jun and Eisenberger, Mario A and Antonarakis, Emmanuel S and Marshall, Catherine H},
title = {Inferred clonal hematopoiesis from tumor DNA sequencing among men with prostate cancer: correlation with somatic tumor alterations and outcomes},
journal = {The Oncologist},
year = {2025},
volume = {30},
number = {4},
doi = {10.1093/oncolo/oyaf049}
}
EUVIMED